Comparison of the Effects of Cilazapril and Captopril versus Placebo on Exercise Testing in Chronic Heart Failure Patients: A Double-Blind, Randomized, Multicenter Tria

Cardiology ◽  
1995 ◽  
Vol 86 (1) ◽  
pp. 34-40 ◽  
Author(s):  
D. Dössegger
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Exercise Testing ◽  
Double Blind ◽  
Heart Failure Patients

scholarly journals A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes

2019 ◽  
Vol 22 (9) ◽  
pp. 1628-1637 ◽  
Author(s):  
Anders Hostrup Larsen ◽  
Niels Jessen ◽  
Helene Nørrelund ◽  
Lars Poulsen Tolbod ◽  
Hendrik Johannes Harms ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Heart Failure Patients ◽  
Insulin Resistant ◽  
Myocardial Efficiency

Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure

2002 ◽  
Vol 103 (s2002) ◽  
pp. 249S-253S ◽  
Author(s):  
Sebastian PHILIPP ◽  
Jan MONTI ◽  
Ines PAGEL ◽  
Thomas LANGENICKEL ◽  
Thomas NOTTER ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Oral Treatment ◽  
Plasma Concentrations ◽  
Second Messenger ◽  
Double Blind ◽  
Heart Failure Patients ◽  
Eta Receptor ◽  
Eta Receptor Antagonist

In heart failure, the cGMP to natriuretic peptide ratio is decreased and infusion of atrial natriuretic peptide (ANP) induces less cGMP generation. The ratio of the second messenger cGMP to plasma concentrations of ANP or brain natriuretic peptide (BNP) correlates with the effectiveness of natriuretic peptides. It was investigated whether blockade of the ETA receptor might improve the cGMP:NP ratio in heart failure. Patients with chronic heart failure (n = 142; mean age = 57 years) received oral treatment with the ETA antagonist darusentan (either 30, 100, 300mg/day or placebo) on top of standard therapy over a period of 21 days in a randomized, double-blind, placebo-controlled, multicentre study. Plasma concentrations of ANP, BNP and cGMP were determined before randomization and after 21 days of treatment. In parallel with decreased pulmonary and systemic vascular resistance, 3 weeks of oral treatment with the ETA receptor antagonist darusentan reduced BNP plasma levels and increased the cGMP:BNP ratio significantly. The improved cGMP:BNP ratio might reflect the ability of chronic ETA receptor blockade to facilitate the generation of the second messenger cGMP, which points towards a favourable modulation of the natriuretic peptide effector system, in addition to haemodynamic improvement in heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document